Climb Bio, Inc.
Clym Therapeutics, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Its pipeline includes budoprutug, an anti-CD19 monoclonal antibody designed to deplete B cells, and CLYM116, an anti-APRIL antibody intended to inhibit APRIL signaling and IgA… From the company’s description.
In fiscal 2025, Climb Bio, Inc. reported a net loss of $59.85M. Operations used $54.36M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Climb Bio, Inc. does
In the company’s own words
Clym Therapeutics, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Its pipeline includes budoprutug, an anti-CD19 monoclonal antibody designed to deplete B cells, and CLYM116, an anti-APRIL antibody intended to inhibit APRIL signaling and IgA production. The company is evaluating budoprutug in primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and is developing an intravenous and a subcutaneous formulation. CLYM116 is in Phase 1 testing for IgA nephropathy and other B-cell-mediated diseases. Clym holds worldwide development and commercialization rights to budoprutug outside oncology, and rights to CLYM116 outside mainland China, Hong Kong, Macau and Taiwan under an agreement with Beijing Mabworks Biotech. The company operates as a single business focused on developing its product candidates and has no product revenue. Its development programs are at clinical stages, including a Phase 2 budoprutug trial in primary membranous nephropathy and Phase 1 trials of CLYM116 and the subcutaneous budoprutug formulation.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WELLESLEY HILLS, MA
- Fiscal year end
- December
- CIK
- 1768446
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Climb Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Climb Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Climb Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Climb Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Climb Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”